MXPA00001497A - Control of enterohemorrhagic e. coli - Google Patents
Control of enterohemorrhagic e. coliInfo
- Publication number
- MXPA00001497A MXPA00001497A MXPA/A/2000/001497A MXPA00001497A MXPA00001497A MX PA00001497 A MXPA00001497 A MX PA00001497A MX PA00001497 A MXPA00001497 A MX PA00001497A MX PA00001497 A MXPA00001497 A MX PA00001497A
- Authority
- MX
- Mexico
- Prior art keywords
- coli
- probiotic bacteria
- strains
- col
- dominant
- Prior art date
Links
- 241000588724 Escherichia coli Species 0.000 title claims abstract description 21
- 241000894006 Bacteria Species 0.000 claims abstract description 113
- 230000000529 probiotic Effects 0.000 claims abstract description 105
- 239000006041 probiotic Substances 0.000 claims abstract description 105
- 235000018291 probiotics Nutrition 0.000 claims abstract description 105
- 230000001580 bacterial Effects 0.000 claims abstract description 15
- 241000282849 Ruminantia Species 0.000 claims abstract description 12
- 210000001035 Gastrointestinal Tract Anatomy 0.000 claims abstract description 9
- 241001646719 Escherichia coli O157:H7 Species 0.000 claims description 81
- 210000003608 Feces Anatomy 0.000 claims description 26
- 210000001519 tissues Anatomy 0.000 claims description 25
- 241000283690 Bos taurus Species 0.000 claims description 24
- 239000000203 mixture Substances 0.000 claims description 23
- 235000013305 food Nutrition 0.000 claims description 11
- 238000002955 isolation Methods 0.000 claims description 10
- 239000000969 carrier Substances 0.000 claims description 8
- 239000012530 fluid Substances 0.000 claims description 8
- 229920003013 deoxyribonucleic acid Polymers 0.000 claims description 7
- 244000144972 livestock Species 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 235000020188 drinking water Nutrition 0.000 claims description 4
- 239000003651 drinking water Substances 0.000 claims description 4
- 230000029087 digestion Effects 0.000 claims description 3
- 230000001079 digestive Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000003550 marker Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims 1
- 244000005700 microbiome Species 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 241001465754 Metazoa Species 0.000 abstract description 38
- 238000011081 inoculation Methods 0.000 abstract description 13
- 230000001717 pathogenic Effects 0.000 abstract description 4
- 244000052769 pathogens Species 0.000 abstract description 4
- 210000004767 Rumen Anatomy 0.000 description 34
- 210000001072 Colon Anatomy 0.000 description 15
- 238000000034 method Methods 0.000 description 13
- 230000002401 inhibitory effect Effects 0.000 description 9
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N 1-ethyl-7-methyl-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 description 8
- 229960000210 Nalidixic Acid Drugs 0.000 description 8
- 238000001514 detection method Methods 0.000 description 8
- 239000001974 tryptic soy broth Substances 0.000 description 8
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 6
- 238000011109 contamination Methods 0.000 description 5
- KCXVZYZYPLLWCC-UHFFFAOYSA-N edta Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 5
- 230000002550 fecal Effects 0.000 description 5
- 235000020183 skimmed milk Nutrition 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 210000001165 Lymph Nodes Anatomy 0.000 description 4
- 210000003491 Skin Anatomy 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 230000002354 daily Effects 0.000 description 4
- 201000008286 diarrhea Diseases 0.000 description 4
- 239000002609 media Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 210000003405 Ileum Anatomy 0.000 description 3
- 210000002741 Palatine Tonsil Anatomy 0.000 description 3
- 206010037660 Pyrexia Diseases 0.000 description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Tris Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 102000004965 antibodies Human genes 0.000 description 3
- 108090001123 antibodies Proteins 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 239000012228 culture supernatant Substances 0.000 description 3
- 201000009910 diseases by infectious agent Diseases 0.000 description 3
- 238000010562 histological examination Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 229920000936 Agarose Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 210000004534 Cecum Anatomy 0.000 description 2
- 210000004953 Colonic tissues Anatomy 0.000 description 2
- 108010067770 Endopeptidase K Proteins 0.000 description 2
- 210000003238 Esophagus Anatomy 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WZUVPPKBWHMQCE-VYIIXAMBSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2C[C@@]2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-VYIIXAMBSA-N 0.000 description 2
- 210000000936 Intestines Anatomy 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L MgCl2 Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 210000004080 Milk Anatomy 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- 210000002787 Omasum Anatomy 0.000 description 2
- 210000000664 Rectum Anatomy 0.000 description 2
- 210000003660 Reticulum Anatomy 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive Effects 0.000 description 2
- 238000009632 agar plate Methods 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000001815 ascending colon Anatomy 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000020828 fasting Nutrition 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 244000144980 herd Species 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000003287 optical Effects 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000003405 preventing Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000001052 transient Effects 0.000 description 2
- 210000003384 transverse colon Anatomy 0.000 description 2
- CPKVUHPKYQGHMW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;molecular iodine Chemical compound II.C=CN1CCCC1=O CPKVUHPKYQGHMW-UHFFFAOYSA-N 0.000 description 1
- BACYUWVYYTXETD-UHFFFAOYSA-N 2-[dodecanoyl(methyl)amino]acetic acid Chemical compound CCCCCCCCCCCC(=O)N(C)CC(O)=O BACYUWVYYTXETD-UHFFFAOYSA-N 0.000 description 1
- 210000003489 Abdominal Muscles Anatomy 0.000 description 1
- 210000003165 Abomasum Anatomy 0.000 description 1
- 241000429837 Alternaria caespitosa Species 0.000 description 1
- 241001600407 Aphis <genus> Species 0.000 description 1
- 101700017503 BACT Proteins 0.000 description 1
- 101700060967 BCN1 Proteins 0.000 description 1
- 229940064804 Betadine Drugs 0.000 description 1
- 240000000218 Cannabis sativa Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 229920002301 Cellulose acetate Polymers 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 108010073254 Colicins Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010061428 Decreased appetite Diseases 0.000 description 1
- 210000001198 Duodenum Anatomy 0.000 description 1
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N Ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 208000000308 Foodborne Disease Diseases 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 210000002216 Heart Anatomy 0.000 description 1
- 210000001630 Jejunum Anatomy 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 210000004185 Liver Anatomy 0.000 description 1
- 241001625930 Luria Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 210000004379 Membranes Anatomy 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- 210000000214 Mouth Anatomy 0.000 description 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 description 1
- 229920002274 Nalgene Polymers 0.000 description 1
- 241000283898 Ovis Species 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 229960001412 Pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N Pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 210000004303 Peritoneum Anatomy 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 210000000952 Spleen Anatomy 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 239000008051 TBE buffer Substances 0.000 description 1
- 210000001550 Testis Anatomy 0.000 description 1
- 210000001541 Thymus Gland Anatomy 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001919 adrenal Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000017585 alfalfa Nutrition 0.000 description 1
- 235000017587 alfalfa Nutrition 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- WHRVRSCEWKLAHX-LQDWTQKMSA-N benzylpenicillin procaine Chemical compound [H+].CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C([O-])=O)(C)C)C(=O)CC1=CC=CC=C1 WHRVRSCEWKLAHX-LQDWTQKMSA-N 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 230000001488 breeding Effects 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001332 colony forming Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003750 conditioning Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 230000001186 cumulative Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000021271 drinking Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 230000027950 fever generation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 235000020993 ground meat Nutrition 0.000 description 1
- 201000001066 hemolytic-uremic syndrome Diseases 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 101700035323 mcbA Proteins 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000000813 microbial Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- 239000012123 non-aqueous mounting media Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 244000045947 parasites Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003449 preventive Effects 0.000 description 1
- 230000002035 prolonged Effects 0.000 description 1
- 238000001711 protein immunostaining Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000405 serological Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000001984 sorbitol MacConkey agar Substances 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 125000002306 tributylsilyl group Chemical group C(CCC)[Si](CCCC)(CCCC)* 0.000 description 1
- 230000002485 urinary Effects 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229960005486 vaccines Drugs 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Abstract
Dominant probiotic bacterial strains have been isolated. The isolated bacterial strains fed to a ruminant animal are able to prevent the establishment of the pathogen i(E. coli) O157:h7 in the animal. The strains can be re-isolated from the gastrointestinal tract contents of inoculated animals at about 28 days post-inoculation. Animals previously infected by i(E. coli) O157:h7 can be treated to reduce or eliminate the pathogen by administering any of the dominant probiotic bacteria of the invention.
Description
CONTROL OF E. COLI 0157.H7 ENTEROHEMORRAGICO IN LIVESTOCK FOR PROBIOTIC BACTERIA
BACKGROUND OF THE INVENTION
E. coli 0157: H7, a major human pathogen that causes hemorrhagic colitis and haemolytic uraemic syndrome, has been reported frequently increased during the past decade as a cause of human disease [for reviews, see Bell. P.B. and collaborators (1994) JAMA 272: 13 9-1353; _Griffin, P.M. and collaborators (1991) Epi demi ol. .Rev. 1_3: 60-98; Padhye, N..Y. and collaborators (1992) J. Food Pro t. 55: 555-565]. Cattle, especially young animals, have been implicated as a major reservoir of E. coli 0157: H7, with undercooked ground meat that is a major vehicle of outbreaks of disease caused by food. Also, the number of outbreaks related to fruits, fruit juices, vegetables (lettuce), and water (including recreational lakes) has increased dramatically in recent years. A recent national surveillance conducted by the National Animal Health Monitoring System of the United States revealed that 1.6% of
REF. : 32508 feedlot scattered fecally E. col i 0157: H7 and 0.4% scattered E. col i 0157: NM [Dagatz, D. (1995) USDA: APHIS: VS, Centers for epidemiology and animal health. Fort Collins, CO (personal communication)]. A larger study of calves in dairy farms revealed that 1.5% that were between the weaning age and 4 months spread E. col i 0157: H7 in their stools [Zhao, T. et al. (1995) Appl. They sent. My crobi ol. 61: 1290-1293], Experimental infection of calves and adult cattle with E. coli 0157: H7 varies widely among animals of the same age group, but persists more in calves than in adults, and previous infection does not prevent reinfection by the same strain of E. coli 0157: H7 [Cray, C. and collaborators (1995) Appl. They sent. My crobi ol. 61: 1585-1590]. Other animals, such as chickens, deer and sheep have also been determined to have the ability to carry E. coli 0157: H7 for a prolonged period of time. Many public health interests have emerged regarding the contamination of food by E. coli 0157: H7. Such interests have been emphasized by the unique acid tolerance of E. coli 0157: H7. Proper cooking is an effective method to kill E. col i 0157: H7 in foods.
However, unsanitary practices in food preparation often result in food-borne illness, and therefore in reducing or eliminating the burden of E. coli 0157: H7 in cattle, it is necessary to reduce public exposure to the pathogen in food and the environment [ang G. et al., (1996) Appl. They sent. My crobi ol. 62_: 2567-2570]. Vaccination has been the traditional procedure to protect livestock from carrying dangerous bacteria. However, E. col i 0157: H7 does not adhere to or infect livestock. The main location sites of E. coli 0157: H7 in calves, are the rumen and the colon. The rumen seems to be the most important site for the long-term carrying of E. coli 0157: H7 and can serve as the source of bacteria found in the colon [Brown, C., et al., (1995) Ve t. Pa th ol. 32: 587], Histological examination of colon tissue revealed no evidence of E. col i 0157: H7 to colon tissue. Therefore the presence of E. coll 0157: H7 in the colon appears to be a transient state through which the bacteria is passing through, rather than colonizing the colon. The vaccines are not likely to be effective in reducing the amount of E. coli 0157: H7 carried and spread by livestock. The amount of E. coli 0157: H7 carried by calves can be affected by nutrition and management practices. Rasmussen et al [(1993) FEMS Microbiol. Lett. 114: 79-84] determined that E. coli 0157: H7 developed unrestricted in the rumen fluid collected from fasted cattle. Some strains of E. coli can produce colicins that inhibit in vitro diarrheogenic E. coli strains, including strains of serotype 0157: H7 [Bradley D.E., et al., (1991) Can J. Microbiol. 3_7: 97-104; Murinda S.E. and collaborators, (1996) App. Environ Microbio! . 62: 3196-3302]. Murinda et al. Tested forty-eight colicin-producing strains of E. coli, and determined that all strains of E. coli 0157: H7 evaluated were sensitive to Col El to E8, K and N on agar containing itomycin C, and also to Col G, Col H and MccB17 on Luria agar. The patterns of sensitivity to colicin and resistance have been used for the identification of the strains. The biological control of a bacterial strain based on its bacteriocin sensitivity has not been achieved.
However, Doyle et al., Patent
North American No. 5,302,388, described the prevention or inhibition of colonization of
Campyl oba c t er j ej uni of the poultry by administering a select bacterial strain capable of competing with C. j ej uni to colonize sites in the caecum of poultry and to inhibit the development of C. j ej uni.
BRIEF DESCRIPTION OF THE INVENTION
The present invention includes the specific strains of E. probiotic coli, its isolation, characteristics and methods of use to prevent or treat the carrying of E. col i 0157: H7 by a ruminant animal. By "probiotic" are meant the bacteria that have the property of preventing the establishment of E. col i 0157: H7 in a ruminant animal previously administered with an effective dose of said probiotic bacteria. For example, calves first administered with an effective amount of a strain of probiotic bacteria, and then subsequently administered with E. coli 0157: H7 do not become carriers of E. col i 0157: H7, while calves administered only with E. coli 0157: H7 continue to carry the strains for weeks, spreading the bacteria to the environment in the feces. Of eighteen probiotic strains isolated in the present study, four were identified as 'dominant', which means that they could be re-isolated from the contents of the gastrointestinal tract of animals inoculated at approximately 28 days after inoculation. the dominant probiotic bacteria are capable of reducing or eliminating E. coli 0157: H7 from calves previously inoculated with E. coli 0157: H7 and carrying the pathogen.The invention therefore provides a method to prevent the carrying of E. coli 0157: H7 by a ruminant, through the step of administering an effective amount of a strain or combination of strains of probiotic bacteria to the ruminant prior to exposure to E. coli 0157: H7.The method is especially useful for treating young ruminants , such as bovine calves, at an early age, before exposure to E. coli 0157: H7, which may be present in the environment. The method is also useful to prevent animals on a feedlot being contaminated at the feedlot. The invention further provides a method for reducing or eliminating E. coli 0157: H7 of a ruminant, to administer an effective amount of a strain or combination of strains of dominant probiotic bacteria. The method is useful to keep herds of cattle free of E. coli 0157: H7 and reduce the portability of E. col i 0157: H7 before slaughtering. The administration of probiotic bacteria is carried out by the administration of a food supplement or additive comprising an effective amount of probiotic bacteria, or by supplying an additive or inoculum of treatment in water to the drinking water of the animals. The invention therefore provides a food supplement composition comprising probiotic bacteria, and a water additive comprising probiotic bacteria. The invention further includes a method for isolating probiotic bacteria, which includes the selection of the supernatant for development of the isolating strains of the stool or intestine, for the ability to inhibit the development of E. coli 0157: H7 on agar. A method for identifying a dominant probiotic bacterium includes the step of inoculating a ruminant animal with a mixture of strains of probiotic bacteria, then isolating the strains of the animal after a defined period of time, for example, of about 4 weeks. Reisolated strains are those that have persisted successfully in the animal, hence the term dominant probiotic bacteria. The reisolation and identification of dominant probiotic strains can be facilitated by the use of marker characteristics, whether endogenous, selected or manipulated by genetic engineering which allow each strain to be identified and / or selected from a mixture. The methods for the isolation of probiotic bacteria, for the isolation of dominant probiotic bacteria, to prevent the contribution of E. col i 0157: H7 and to treat an animal to reduce or eliminate E. coli 0157: H7 of the animal, are all applicable to other animals besides cattle, especially other ruminants, which have been observed to carry E. coli 0157: H7. To date, the cattle are the most numerous carriers of E. coli 0157: H7. The methods of isolation and use of the dominant probiotic strains are achieved by studies carried out with livestock. A large number of strains are available from natural sources, which can meet the criteria of probiotic and dominant probiotic bacteria. The repeats of the isolation process described herein may yield the same or different strains as those described herein. Such strains fall within the general categories of probiotic and dominant probiotic bacteria, as described herein.
DESCRIPTION OF THE DRAWINGS
Figure 1 is a graph - showing the destination of E. coli 0157: H7 in the calf rumen fluid to which only E was administered. col i 0157: H7. The arrow indicates the detection of E. col i 0157: H7 only by an enrichment procedure. Figure 2 is a graph showing the destination of E. col i 0157: H7 in feces of calves to which only E was administered. coli 0157: H7. The arrow indicates the detection of E. col i 0157.H7 only through an enrichment procedure. Figure 3 is a graph showing the destination of E. coli 0157: H7 in the rumen fluid of calves given probiotic bacteria and two days subsequently E. col i 0157: H7. The arrow indicates the detection of E. coli 0157: H7 only by an enrichment procedure. Figure 4 is a graph showing the destination of E. coli 0157: H7 in calf feces that were given probiotic bacteria and two days subsequently E. coli 0157: H7. The arrow indicates the detection of E. col i 0157: H7 only by an enrichment procedure. Figure 5 is a graph of the destination of E. col i 0157: H7 in the rumen fluid of calves to which E was administered. coli 0157: H7 only. The arrow indicates the detection of E. coli 0157: H7 only by an enrichment procedure. Figure 6 is a graph of the destination of E. col i 0157: H7 in feces of calves to which E was administered. coli 0157: H7 only. The arrow indicates the detection of E. coli 0157: H7 only by an enrichment method. Figure 7 is a graph of the destination of E. col i 0157: H7 in the rumen fluid of calves treated with dominant probiotic bacteria, 1 to 3 days after administration of E. col i 0157: H7. The arrow indicates the detection of E. col i 0157: H7 only by an enrichment procedure. Figure 8 is a graph of the destination of E. coli 0157: H7 in feces of calves treated with the dominant probiotic bacteria, 1 to 3 days after administration of E. col i 0157: H7. The arrow indicates the detection of E. col i 0157: H7 only by an enrichment procedure. Figure 9 describes the digestions with
Xbal of the genomic DNA of the dominant probiotic bacteria by pulsed-field gel electrophoresis. The left and right bands are the stairs? (48.5 kb). Bands 1 to 8 are strain 271. Figure 10 describes the Xbal digestions of the genomic DNA of the dominant probiotic bacteria by pulsed-field gel electrophoresis. The left and right bands are the stairs? (48.5 kb). Band 1 is strain 786, and bands 2 through 6 are strain 797.
DETAILED DESCRIPTION OF THE INVENTION
Histological examination of colonic tissue has not revealed evidence of E adhesion. col i 0157: H7 to bovine colonic tissue. The rumen seems to be the most important site for the long-term carrying of E. col i 0157: H7. The presence of the 0157-H7 bacteria in the colon is considered to be a transient state, with the bacteria passing through from the source of the rumen and being scattered in the feces. Animals can be initially infected by ingestion of contaminated grass, feed or water. The results of the present study show that E. coli 0157: H7 persists in the regimens of untreated calves up to 30 days after a single inoculant dose, and scattered in the feces throughout the same period of time. The 057: H7 bacteria are therefore carried by the cattle along with any other microbial strains that inhabit the digestive tract of the animals. For purposes of this invention, cattle and other animals in whose tissues or feces can be detected E. col i 0157: H7 is said to carry E. col i 0157: H7. The amount of E. col i 0157: H7 carried by each animal, is measurable in different ways, including taking samples from various tissues. More conveniently, the presence of E. coli 0157: H7 can be measured in stool. Such measurement is of practical importance, since fecal contamination is the apparent source of contamination of the meat and also of the reintroduction and infection of other animals. As shown herein, the amount of S. coli 0157: H7 scattered in the stool is reflected in the amount measurable in the rumen. Therefore, the amount of E. col i 0157: H7 in feces is a measure of the amount carried by the animal. The quantitative measurement of E. coli 0157: H7 is expressed as colony forming units (CFU) per gram of faeces or per milliliter of rumen. * Probiotic "is used in the present as an adjective to describe bacteria isolated from a natural source and which has the property of inhibiting the development of E. coli 0157: H7.The test of an inhibition used in the present was a test in vi On a solid medium in which the culture supernatants of the isolated candidate bacteria were observed for their property of inhibiting the development of E. coli 0157: H7 when applied to the surface of the solid medium, typically an impregnated paper disc with the culture supernatant of a candidate strain was placed on the surface of an agar plate seeded with E. coli 0157: H7.The probiotic bacterial supernatants caused a ring of clear agar or of reduced growth density, indicating the inhibition of E. coli. coli 0157: H7 in the vicinity of the disc There are other tests for inhibition that are available or could be considered, including competency tests and direct growth, vi n vi o vi n vi, which can generate a panel of probiotic bacteria similar to those described herein. The bacterial strains identified by such a test are within the category of probiotic bacteria, as the term is used herein. The term "dominant probiotic" is applied in probiotic bacteria that persist in, and are reaisable from, an animal to which the bacteria have been administered.The criterion used in the work described here was reisolation 26 days after inoculation The bovine calves were fed with a mixture of 18 probiotic strains, then, from a variety of tissues, samples of digestive contents and feces were taken 26 days after inoculation Four strains were retrievable, designated probiotic strains Other criteria may be employed, including shorter or longer periods of time between inoculation and sampling.It is advisable to choose a sufficiently long period of time, so that the persistence of the dominant probiotic strains can provide useful reduction of the amount of E. coli 0157: H7 carried by the animal The isolation of the bacteria Dominant probiotics can be carried out by those of ordinary skill in the art, following the principles and procedures described herein. Of 1200 isolated colonies of feces and cattle tissues, 18 were probiotic and 4 were dominant probiotics. Therefore, testing similar numbers of independent isolates is likely to reasonably and successfully produce probiotic dominant bacteria. The administration of dominant probiotic bacteria can be carried out by any method that probably introduces organisms into the digestive tract. Bacteria can be mixed with a carrier and applied to liquid or solid food or drinking water. The carrier material must be non-toxic to bacteria and to the animal. Preferably, the carrier contains an ingredient that promotes the viability of the bacteria during storage. The bacteria can also be formulated as an inoculant paste to be directly injected into the animal's mouth. The formulation may include added ingredients to improve palatability., improve shelf life, impart nutritional benefits, and the like. If a reproducible and measured dose is desired, the bacteria can be administered by a rumen cannula, as described herein. The amount of dominant probiotic bacteria that will be administered is governed by factors that affect efficacy. In the present study, 1010 CFU were administered in a single dose. Lower doses may be effective. When it is administered in food or drinking water, the dose can be spread over a period of days or even weeks. The cumulative effect of lower doses administered in several days may be greater than a single dose of 1010 CFU. By periodically checking the numbers of E. col i 0157: H7 in faeces before, during and after administration of the dominant probiotic bacteria, those skilled in the art can easily assess the level of dose necessary to reduce the amount of E. coli 0157: H7 carried by the animals. One or more strains of dominant probiotic bacteria can be co-administered. A combination of strains may be advantageous, because the individual animals may differ in the strain that is more persistent in a given individual. The dominant probiotic bacteria can be administered as a preventative, to prevent animals that do not currently carry E. coli 0157: H7 acquire the strain by exposure to other animals or to environments where E is present. col i 0157: H7. Young calves and mature animals coming to be transferred to a new site, such as a feedlot, are attractive candidates for preventive management. The treatment of animals that carry E. col i 0157: H7 can be carried out to reduce or eliminate the amount of E. coli 0157: H7 carried by the animals, by administering a dominant probiotic bacteria to animals infected with E. col i 0157: H7. The animals that are known are dispersing E. col i 0157: H7 in the stool, or those produced where it is known that E. coli 0157: H7 exists, are suitable candidates for treatment with dominant probiotic bacteria. The methods for administering dominant probiotic bacteria are essentially the same, either for prevention or treatment. Therefore, the need to determine first if E. coli 0157: H7 is being carried by the animals, it is eliminated. By routinely administering an effective dose to all animals in a herd, the risk of contamination by E. col i 0157: H7 can be substantially reduced or eliminated by a combination of prevention and treatment.
EXAMPLES
Example 1. Isolation of Probiotic Bacteria
Probiotic bacteria were isolated from cattle feces or from gastrointestinal tissue of cattle (intestine and colon). Faecal samples were collected from the cattle that were confirmed as negative for E by faecal test. col i
0157: H7. Fecal samples were serially diluted (1:10) in 0.1 M phosphate buffer, pH 7.2
(PBS) and 0.1 ml of each dilution was placed in plates, on sorbitol-MacConkey agar plates (SMA). The plates were incubated for 16 hours at 37 ° C and up to 10 colonies were randomly selected and each transferred to a test tube containing 10 ml of chicken broth Tripticase (TBS) [(BBL, Becton Dickinson, Cockeysville, MD). The cultures were incubated for 16 hours at 37 ° C. The tissue samples (1 g each) were homogenized (Ultra-Turrax Homogenizer T25, Janke &Kundel IKA-labortechnik, Germany) at 9,500 rpm for 1 minute and then 0.1 ml portions were plated on the surface of the plates. of SMA. The plates were incubated for 16 hours at 37 ° C. Up to 10 colonies were each transferred to test tubes containing 10 ml of TSB and incubated for 16 hours at 37 ° C. The supernatant fluid from each culture was sterilized by filtration (0.2 μm cellulose acetate membrane, Nalgene Co., Rochester, NY).
Example 2. Crop Selection for Anti-i Properties ?, coli 0157.H7
A mixture of 5 strains of E. coli 0157: H7, including strains 932 (human isolate), C7927 (human isolate), E009 (meat isolate), E0018
(cattle isolate) and E0122 (cattle isolate) was used to select culture supernatants for anti-J? metabolites. coli 0151: The.
Approximately 107 E. coli 0157: H7 from approximately equal populations of each strain in 0.1 ml were plated onto surface in SMA and TSA in duplicate. A disc (12 mm in diameter) was placed on the surface of each SMA and TSA plate and 0.1 ml of sterile supernatant was filtered by a simple culture and applied to the disc surface. In addition, a disc with 70% ethanol (positive control) and a disc with PBS (negative control) were applied to each plate. The cultures were incubated for 18 hours at 37 ° C and observed for the zones of inhibition. A clear area of more than 1 mm was considered a positive response.
Example 3. Preparation of Col cultures i 0157: H7
The same mixture of 5 strains described above was used. To facilitate the counting of these bacterial isolates, the strains were induced for resistance to nalidixic acid (50 μg / ml). Each strain of E. coli 0157: H7 resistant to nalidixic acid was transferred to 10 ml of tryptic soy broth (TSB) containing nalidixic acid (50 μg / ml) and incubated for 16-18 hours at 37 ° C with shaking (150 rpm). A suspension of 2 ml of each isolate was transferred to 300 ml of TSB. After incubation at 37 ° C for 16 to 18 hours, the bacteria were pelleted by centrifugation (4,000 x g for 20 minutes) and washed 3 times in PBS. The PBS was added to the sedimented bacteria in an amount necessary to obtain an optical density (O.D.) of 0.5 to 630_ nm (108 CFU / ml). A mixture of the 5 isolates (2 x 109 CFU of each strain) of E. col i 0157.H7 was mixed in 250 ml of 2% sterilized skim milk just before the oral inoculation of the calves. Bacterial populations were confirmed by counting on TSA and SMA plates containing nalidixic acid (50 μg / ml, SMA-NA).
Example 4: Preparation of Probiotic Bacteria
All probiotic bacterial isolates were selected for resistance to nalidixic acid (50 μg / ml) for ease of counting in feces. The bacteria were individually developed in 10 ml of TSB containing nalidixic acid (50 μg / ml). A 1 ml portion of each isolate was transferred to 100 ml of TSB. After incubation at 37 ° C for 16 to 18 hours, the bacteria were sedimented by centrifugation, washed, and adjusted to an optical density at 630 nm of 0.5, using the method described above. The 18 strains of probiotic bacteria (1010 CFU) were mixed in 250 ml of sterilized skim milk, 2% just before the oral inoculation of the calves. The bacterial population was confirmed by counting the serial dilutions on TSA and SMA-NA plates in duplicate.
Example 5 Preparation of the Calves
Fifteen male milk calves from a single source were bred with a milk replacer and weaned at 6 weeks of age before transferring them to the University of Georgia. The calves were housed individually in rooms of concrete BL-2 climate controlled. Each room had a single floor drain and were cleaned once a day. The calves were fed a mixture of alfalfa pellets and sweet food twice a day and had free access to water. During a 2-week conditioning period, fecal samples from all calves were taken and tested as negative, via fluorescent antibody staining, for bovine virus diarrhea, coronavirus, rotavirus, pilus E antigens. col i, and Crypt ospori di a. Fecal flotation for intestinal parasites and bacterial culture for Salmonel l and E. coli 0157: H7, was performed and the fecal pH was determined. After a preconditioning period of 2 weeks, the calves were surgically equipped with cannulas in the rumen (flexible cannula for rumen). They were allowed at least 10 days to recover from the surgery and were given the necessary care before the experiment began.
Example 6 Cannulation of the Rumen
The food was removed from the calves for 12 hours. The left paralumbar fossa was sheared and cleaned for standard surgical preparation. The fossa was anesthetized by using a paravertebral nerve block, the inverted L block, Lidocaine, slightly smaller than the local anesthetic, a circular incision was made, slightly smaller than the diameter of the cannula, and the circular piece of skin and the underlying external abdominal and cuticular oblique muscles were removed.The vessels were ligated as necessary and the oblique transverse abdominal muscles, internal, and peritoneum were separated and retracted leaving them blunt to create an opening to expose the wall The rumen wall was clamped with two large towel clamps, for traction, to exteriorize the rumen.The rumen wall was then sutured to the skin using cat # 3 or vetafil gut incorporating the muscle layers with a skin pattern. continuous suture The incision was made in the wall of the rumen and a circular piece of the rumen was removed and the cannula was inserted . Calves were treated for 5 days after surgery procaine penicillin G intramuscularly. The area between the cannula and the rumen wall was gently cleaned daily with betadine solution.
Example 7 Inoculation of Calves
After 12 hours of fasting, the calves were inoculated via cannulation of the rumen with 250 ml of skimmed milk containing probiotic bacteria. After 48 hours, the mixture of 5 strains of E. coli 0157: H7 was inoculated via the same route. The control calves were challenged with the mixture of 5 strains of E. coli 0157: H7 only. After the challenge, the calves were examined daily for clinical signs including depression, pyrexia, diarrhea and anorexia. The rectal stools or samples collected from the fiscular tube were determined for pH, and the count of E. coli 0157: H7 and probiotic bacteria. Isolation and Counting of Inocula
Bacteria: A 10 g sample of stool or rumen content was collected through cannulation of rectum or rumen recovery daily after inoculation of E. coli 0157: H7. The samples were placed in a tube containing 15 ml of Cary-Blair transport medium, kept at 5 ° C, and transported to the Center for Food Safety and Quality Improvement (Center for Food Safety and Quality Enhancement) for analysis . A volume containing 1 g of faeces was serially diluted (1:10) in 0.85% sodium chloride to 10"6, and 0.1 ml of each dilution was placed in duplicate on SMN-NA. complete gastrointestinal, collected at necropsy were contained at 5 ° C until analysis. The content of each tissue from each segment was separated and weighed, and the tissue was rinsed with 100 ml of PBS. The rinsed tissue was d to 9 ml of PBS and homogenized for 1 minute at 9,500 rpm with an Ultra-Turrax tissue homogenizer. A sample of 0.1 ml of tissue or suspension of tissue content was inoculated onto SMA-NA plates in quadruplicate and incubated at 37 ° C for 24 hours for the E count. coli 0157: H7 or probiotic bacteria. If these bacteria were not detected by the direct plating method, a selective enrichment method (17) (modified TSB containing 50 μg of nalidixic acid / ml) was performed. The samples were each placed in 100 ml of selective enrichment medium and incubated at 37 ° C for 24 hours with shaking at 150 rpm. The dilutions of the cultures were plated on SMA-NA and the isolates were selected and subsequently tested. The typical colonies of E. coli 0157: H7 (negative sorbitol) were seeded again on plates on SMN-NA and confirmed as E. coli by biochemical methods, and as 0157 and H7 by serological methods. The probiotic bacteria were confirmed by DNA fingerprinting by pulsed-field gel electrophoresis (PFGE).
Example 8. Genomic Fingerprint of Bacterial Isolates
The PFGE procedures similar to those previously described were used
(14) The bacteria were developed in 10 ml of
TSB at 37 ° C for 24 hours with agitation at 200 rpm. The bacteria were sedimented by centrifugation
(4000 X g, 20 minutes), washed three times in 75 mM NaCl containing 25 mM EDTA at pH 7.4 (SE), and resuspended in 0.5 ml of SE. The bacterial suspension was mixed with 0.5 ml of 2% (w / v) low melting point agarose in buffer consisting of 10 mM Tris, 10 mM magnesium chloride and 1 mM EDTA (ME), pH 7.5. This mixture was supplied in sample molds and the agarose plugs were digested with proteinase K (2 mg proteinase K, 50 mM Tris, 50 mM EDTA, 1% N-lauroyl sarcosine / ml, pH 8.0) at 5 ° C the night. The samples were washed in 10 mM Tris, 5 mM EDTA, pH 7.5 (TE), and digested with 50 U of Xbal. After incubation at 37 ° C overnight, the reaction was stopped by the addition of 20 μl of 0.5 M EDTA. The DNA samples were subjected to electrophoresis on a 1.2% agarose gel in 0.5 X TBE buffer for a homogeneous electric field device, with clamp on the contour (CHEF MAPPER, BioRAd). After electrophoresis for 24 hours at 200 V with pulse times of 5-50 seconds and linear inclination and an electric field angle of 120 ° C to 14 ° C, the gels were stained with ethidium bromide and the bands were visualized and photographed with UV transillumination. The results for 3 dominant probiotic strains, 271, 786 and 797 are shown in Figures 9 and 10.
Example 9 Carcass Necropsy
The calves were sacrificed with intravenous sodium pentobarbital. The gastrointestinal tract was pinched in the esophagus and rectum and completely removed. Stretches of four to six cm of the duodenum, proximal, intermediate, middle, and distal jejunum, proximal and distal ileum, proximal and distal caecal bow, proximal curl of the ascending colon, centripetal and centrifugal spin of the spiral colon, transverse colon, and colon descending were double bound to allow sampling of all sections for the count of E. coli 0157: H7 and the probiotic bacteria in the tissue, and their content with minimal cross-contamination. Sections and contents of the rumen, reticulum, omasum and abomasum, and sections of kidney, spleen, liver, gallbladder, lymphoid jejunal lymph node, lymph node, cecal lymph node and tonsil were also collected for culture and counting of E coli 0157: H7 and / or probiotic bacteria. Sections from all of these sites, as well as sections of the prescapular lymph node, skeletal muscle, skin, tonsil, thyroid, thymus, esophagus, heart, pancreas, navel, adrenal, urinary vegija, and testicles were also placed in formalin 10 % buffered for histological examination.
Example 10. Histopathology and Immunohistochemistry of Tissues
Fixed tissues were embedded in paraffin by standard methods, sectioned at 5 μm and stained with hematoxylin and eosin. The selected sections were stained with Gram. Sections showing large numbers of surface or luminal bacteria histologically were selected and treated by an alkaline phosphatase immunostaining procedure to identify E. coli 0157: H7. The tissues were deparaffinized in xylene for 10 minutes, rehydrated through gradient alcohols, and rinsed in PBS. The sections were covered with the specific antibody of E. col i 0157: H7 (Kirkegaard &Perry Laboratories, Inc., Gai Thersburg, MD) and incubated in a humidity chamber for 30 minutes at room temperature. After a 10 minute rinse in PBS, the slides were covered with a biotin-labeled second antibody for 20 minutes in a humid chamber at room temperature. The slides were rinsed for 10 minutes in PBS, returned to the humidity chamber, and the tissue sections were covered with conjugated streptavidin alkaline phosphatase. After incubation at room temperature for 20 minutes, the slides were rinsed in PBS for 10 minutes, placed in the humidity chamber, and bathed in a substrate solution for 15 minutes. The slides were rinsed in PBS for 10 minutes, counterstained for 3 minutes with Mayer's hematoxylin, mounted with aqueous medium followed by the non-aqueous mounting medium, and examined microscopically.
Example 11 Quantities of coli 0157: H7 carried in the absence and presence of probiotic bacteria
Selection in vitro of potential probiotic bacteria that secrete inhibitory metabolism (s) to E. coli 0157: H7. Eighteen of 1,200 colonies isolated from cattle tissue and feces inhibited E. coli 0157: H7 i n vi tro. Among them, five colonies were isolated from faeces, five from the small intestine, and eight from the colon. Seventeen of the 18 colonies were identified as E. coli and the others as Pro t eus mi rabili s. All were evaluated for Shiga toxin production and none produced Shiga toxin. The fingerprint of the genomic DNA of PFGE revealed 13 different profiles among the 18 isolates.
Colonization of calves by probiotic bacteria. One calf was initially fed a strain of probiotic bacteria (E. coli with 1010 CFU). The calf appeared to be normal, and this E. col i was recovered by the enrichment procedure from only the ileum and the caecum at the termination of the experiment (12 days). Two calves were then fed with the 18 complete strains (approximately equal concentrations, 5 x 108 CFU each) of probiotic bacteria (1010 CFU / per calf) as a mixture. The feces of the calves were of normal consistency and the bacteria colonized the gastrointestinal tract for up to 27 days (at the end of the study the counts were 50 to 200 CFU / g of feces).
Determination of dominant probiotic bacteria strains by PFGE. Twenty-one colonies isolated from the tonsil, omasum, reticulum, proximal ileum, distal caecal bowel, proximal curl of the ascending colon, transverse colon, and stool at 26 days after inoculation were analyzed by PFGE. The isolates with four DNA profiles were dominant and all were JE7. coli Among the twenty-one colonies, nine were from strain # 797, seven were from strain # 786, three were from strain # 721, and two were from strain # 1019.
Pathological changes in calves by probiotic bacteria. Although some strains of the inoculated bacteria were recovered at necropsy from tissue specimens from different parts of the gastrointestinal tract, there were no pathological changes in any of the tissue samples evaluated.
Efficiency of probiotic bacteria to reduce the carrying of E. coli 0157: H7 in calves.
Of the 9 calves to which they were administered only E. coli 0157: H7, all remained healthy without evidence of fever or diarrhea. E. coli 0157: H7 was intermittently isolated from the rumen fluid of all animals during 3 weeks after inoculation (Figure 1). The dispersion of E. coli 0157: H7 in stools at various levels was continuous throughout the experiment (average 28 days) (Figure 2). At the necropsy, E. col i 0157: H7 was isolated from the rumen contents of eight out of ten, and colon from 10 out of 10 calves. No pathological changes of any of the tissue samples examined were observed. All calves given probiotic bacteria 2 days before treatment with E. coli 0157: H7 remained healthy without evidence of fever or diarrhea. E.
coli 0157: H7 was detected in rumen samples collected through the fistula tube, up to 9 days in two animals, 16 days in an animal, 17 days in two animals, and 29 days in an animal (Figure 3). E. coli 0157: H7 was detected in feces for up to 11, 15, 17, 18, 19, and 29 days (at the end of the experiment) in each of the animals (Figure 4). At necropsy (average 30 days), E. coli 0157: H7 was not recovered from the rumen samples of any of these six animals; however, these bacteria were recovered from the colon of one of the six animals. The animal positive to E. col i 0157: H7 was twice fasted for periods of 2 days (day 16, 17 and day 23, 24) after inoculation during the study. Four of the six animals treated with probiotic bacteria were fasted according to this protocol.
Example 12. Efficacy of Dominant Probiotic Bacteria as a Treatment to Reduce / Eliminate E. col i 0157: H7 in Cattle
Preparation of Dominant Probiotic Bacteria. Four strains of E. coli (271, 797, 786 and 1019) previously determined as inhibitors of E. coli 0157: H7, were selected for resistance to nalidixic acid (50 μg / ml) for ease of counting in feces. Approximately equal populations of each of the four stages were mixed (total 10 10 CFU) in 50 ml of skimmed milk sterilized at 2% for administration to calves. The populations of E. coli were confirmed by duplicate counting of TSA and SMA-NA plates.
Inoculation of calves. A total of 16 calves were used. After a period of 24 hours of fasting, each was administered a mixture of 5 strains of E. col i 0157: H7 in 50 ml of skimmed milk 2% sterile (1010 CFU) through a cannula tube. Two calves were treated with probiotic bacteria (1010 CFU) through a cannula tube 1 day after the administration of E. coli 0157: H7. Two additional calves were treated with probiotic bacteria (1010 GFU) 3 days after the administration of E. coli 0157: H7. The rumen samples collected through the tube of the cannula and rectal stools were counted daily for E. coli 0157: H7 and the probiotic bacteria.
Efficiency of the treatment of probiotic bacteria in the reduction / elimination of the carrying of E. coli 0157: H7 in calves. Of the 12 calves to which they were administered only E. col i 0157: H7 as positive controls, 0157 was isolated intermittently from the rumen for up to 2 weeks from 1 animal, for 3 weeks from 3 animals, and for 4 weeks from 8 animals (Figure 5). The continuous dispersion of E. coli 0157: H7 at various levels in the feces of 11 of 12 calves occurred throughout the study (Figure 6). At necropsy, E was isolated. col i 0157: H7 of the contents of the rumen of 9 of 12 calves and of the colon of 10 of 12 calves. Four calves were treated with a mixture of four strains of probiotic bacteria
(strains 271, 786, 797, and 1019) 1 to 3 days after administration of E. col i 0157: H7. E. coli
0157: H7 was detected in rumen samples up to 6 days in 1 animal, 8 days in two, and 9 days in one
(Figure 7). E. col i 0157: H7 was detected in feces for up to 10 days in two animals, 11 days in one, and
days in one (Figure 8). At a necropsy (two at
22 days and two at 27 days), E. coli 0157: H7 was not recovered from the rumen or colon samples (tissue or contents) of any of these four animals. Only strains 271, 786 and 797 of the probiotic bacteria were recovered from the four animals at the end of the study. Strain 1019 was not detected in any of the animals at the time of the necropsy. The examples above illustrate the principles and practices for preventing and treating the carrying of E. col i 0157: H7 by administering probiotic or dominant probiotic bacteria to an animal carrying E. coli 0157: H7. Strains 271, 786 and 797 of E. coli were isolated and showed to be dominant probiotic bacteria. From the ease of isolation and the number of strains obtained, it is evident that other dominant probiotic strains can be isolated and used to inoculate cattle or other animals to prevent or treat the carrying of E. coli 0157: H7. Different strains can be advantageous for different applications depending on the animal species, breeding, age, diet, housing environment and management practices. All bacterial strains of this type, isolated and / or used as generally described herein to effectively reduce or eliminate the amount of E. coli 0157: H7 carried by an animal, are within the scope of the invention. Administration methods capable of providing an effective dose of probiotic or probiotic dominant bacteria to an animal, include a variety of feeding, drinking, and other administration methods known in the art, using a variety of formulations containing the bacteria, all within the scope of the invention. All such variations and modifications, based or derived from the teachings and descriptions herein, are considered within the scope of the appended claims. The following strains are deposited with the American Collection of Species (American Type Culture Collection) in accordance with 37 CFR 1.801-1.809: E. col i 271 ATCC Access No. 202020, August 13, 1997 E. coli 786 ATCC Access No. 202018, 13
August 1997 E. coli 797 ATCC Access No. 202019, August 13, 1997 It is noted that in relation to this date, the best method known to the applicant to carry out said invention is that which is clear from the present description of the invention. invention
Claims (13)
1. A microorganism selected from the group of dominant probiotic bacteria, characterized in that they consist of E. col i 271, E. col i 786, E. col i 797 and E. coli 1019.
2. A method for selecting dominant probiotic bacteria, characterized in that it comprises the steps of: the isolation of bacterial strains of natural origin from the fluids of ruminant animal tissues, digestive contents or feces, and the obtaining of isolated strains: the cultivation of strains isolated in liquid or solid media; the individual test for the ability of each isolated strain to inhibit E growth. col i 0157: H7 in vi tro, thereby strains that have the ability to inhibit the growth of E. coli 0157: H7 in vi tro are identified as probiotic bacteria, the subculture of probiotic bacteria, and the administration of one or more strains of probiotic bacteria to a ruminant animal, and isolating again the probiotic bacteria reaisables from the digestive contents or the faeces of said animal, after a predetermined time, whereby the rearabilable probiotic bacteria are identified as dominant probiotic bacteria.
3. The method according to claim 2, characterized in that the probiotic bacteria are provided with a selectable marker trait.
4. The method according to claim 2, characterized in that the probiotic bacteria are distinguishable from one another by digestion patterns of restriction fragments. DNA
5. The method according to claim 2, characterized in that the animal is a bovine.
6. A method to prevent or treat the carrying of E. coli 0157: H7 by a ruminant animal, characterized in that it comprises administering an effective amount of one or more strains of the dominant probiotic bacteria selected according to the method according to claim 3, to the digestive tract of said animal.
7. The method according to claim 6, characterized in that the dominant probiotic bacterium is selected from the group of E. coli 271, E. coli 18 6, or E. coli 797.
8. The method according to claim 6, characterized in that the dominant probiotic bacterium is administered in a series of doses combined with the drinking water.
9. The method according to claim 6, characterized in that the dominant probiotic bacteria is administered in a series of doses combined with the food.
10. The method according to claim 6, characterized in that the animal is a bovine.
11. An "igniter" composition, characterized in that it comprises a carrier and one or more strains of dominant probiotic bacteria selected from a group consisting of E. coli 271 ATCC 202020, E col i 786 ATCC 20218 and E. coli ATCC 20219.
12. The composition according to claim 11, characterized in that the carrier comprises water.
13. The composition according to claim 11, characterized in that the carrier comprises a substance edible by livestock.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08910850 | 1997-08-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA00001497A true MXPA00001497A (en) | 2001-05-07 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5965128A (en) | Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli | |
Fairbrother et al. | Colibacillosis | |
Zhao et al. | Reduction of carriage of enterohemorrhagic Escherichia coli O157: H7 in cattle by inoculation with probiotic bacteria | |
Kudva et al. | Effect of diet on the shedding of Escherichia coli O157: H7 in a sheep model | |
Gharib et al. | Comparison of the effects of probiotic, organic acid and medicinal plant on Campylobacter jejuni challenged broiler chickens | |
Aarestrup et al. | Nonhuman reservoirs of enterococci | |
KR20010031131A (en) | Competitive exclusion culture for swine | |
Oliver et al. | Foodborne pathogens, mastitis, milk quality, and dairy food safety | |
HUT74951A (en) | Probiotic for control of salmonella | |
WO2007058027A1 (en) | Harmful bacterium control agent containing bacillus thuringiensis | |
Al‐Tarazi et al. | Effect of dietary formic and propionic acids on Salmonella pullorum shedding and mortality in layer chicks after experimental infection | |
US20050031732A1 (en) | Health and/or nutritional status of an aquatic animal | |
Aho et al. | Competitive exclusion of campylobacters from poultry with K-bacteria and Broilact® | |
Murayama et al. | Effects of orally administered Clostridium butyricum MIYAIRI 588 on mucosal immunity in mice | |
Sanchez et al. | Animal issues associated with Escherichia coli O157: H7 | |
Barnhart et al. | Evaluation of potential disinfectants for preslaughter broiler crop decontamination | |
Kassaify et al. | Effect of food protein supplements on Salmonella Enteritidis infection and prevention in laying hens | |
Atroshi et al. | The effect of dietary exposure to DON and T‐2 Toxin on host resistance and serum immunoglobins of normal and mastitic mice | |
WO1998047521A1 (en) | Phages, methods for growing and detecting them and their use | |
Ibrahim et al. | Antibacterial activity of doxycycline against Aeromonas hydrophila in experimentally challenged African catfish (Clarias gariepinus) | |
MXPA00001497A (en) | Control of enterohemorrhagic e. coli | |
Marciňáková et al. | Effect of potential probiotic activity of Enterococcus faecium EE3 strain against Salmonella infection in Japanese quails | |
Boldura et al. | Traceability of transgenic soybean from forage trough animal tissue till the food product | |
Elhofy et al. | The effect of thyme (thymus vulgaris) extract on Escherichia coli in diarrheic calves with study of its immunological effect. | |
Nakamura et al. | Prevention of drug‐resistant Escherichia coli colonization in chickens by treatment with a faecal fluid |